IP Library Granted Patent US 10,202,593
Granted Patent B2
US 10,202,593 · App. 15/022,985 · Granted Feb 12, 2019

Evolved sortases and uses thereof

Inventors: David R. Liu (Lexington, MA); Brent M. Dorr (Somerville, MA)
Assignee: President and Fellows of Harvard College
C12N9/52C07K14/473C12P21/00C12P21/02C12Y304/2207
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,202,593
App. No.
15/022,985
Granted
Feb 12, 2019
Kind
B2
Abstract

Evolved sortases exhibiting enhanced reaction kinetics and/or altered substrate preferences are provided herein, for example evolved sortases that bind recognitions motifs comprising a LAXT or LPXS sequence. Also provided are methods (e.g., orthogonal transpeptidation and diagnostics methods) for using such sortases. Kits comprising materials, reagents, and cells for carrying out the methods described herein are also provided.

Claims (34)

1. A Staphylococcus aureus ( S. aureus ) Sortase A variant that binds substrates comprising the sequence LAXT, wherein X represents any amino acid, and wherein the S. aureus Sortase A variant comprises an amino acid sequence that is at least 90% identical to the amino acid sequence of S. aureus Sortase A as provided as SEQ ID NO: 1, and wherein the amino acid sequence of the Sortase A variant includes a mutation selected from the group consisting of K84R, R99H, R99K, S102C, A104H, E105D, K138I, K138V, K138P, K145E, K152I, D160K, K162R, K162H, T164N, V168I, K177G, K177R, I182F, and K196S.

2. The Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 1 , wherein the S. aureus Sortase A variant comprises an amino acid sequence that is at least 95% identical to the amino acid sequence provided in SEQ ID NO: 1.

3. The Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 1 , wherein the amino acid sequence of the S. aureus Sortase A variant comprises at least two mutations, as compared to the amino acid sequence of S. aureus Sortase A provided as SEQ ID NO: 1.

4. The Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 1 , wherein the substrate comprises the amino acid sequence LAXTX, wherein each occurrence of X independently represents any amino acid.

5. The Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 1 , wherein the substrate comprises the amino acid sequence LAETG (SEQ ID NO: 5).

6. A Staphylococcus aureus ( S. aureus ) Sortase A variant that binds substrates comprising the sequence LPXS, wherein X represents any amino acid, the S. aureus Sortase A variant comprising an amino acid sequence that is at least 90% identical to the amino acid sequence of S. aureus Sortase A as provided as SEQ ID NO: 1, wherein the amino acid sequence of the Sortase A variant includes a mutation selected from the group consisting of N98D, S102C, A104V, A118S, A118T, F122A, K134G, K134P, E189V, E189F, and E189P.

7. A method for transpeptidation, the method comprising contacting the S. aureus Sortase A variant of claim 1 with a substrate comprising an LAXT amino acid sequence, wherein X represents any amino acid, and a substrate comprising a GGG sequence under conditions suitable for sortase-mediated transpeptidation.

8. A method for transpeptidation comprising contacting the Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 6 with a substrate comprising an LPXS amino acid sequence, wherein X represents any amino acid, and a substrate comprising a GGG sequence under conditions suitable for sortase-mediated transpeptidation.

9. A method for N-terminal protein modification comprising contacting a protein comprising a N-terminal GGG sequence with the Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 1 , and a sortase substrate comprising a LAXT sequence, respectively, under conditions suitable for sortase-mediated transpeptidation, wherein X represents any amino acid.

10. A method for C-terminal protein modification comprising contacting a protein comprising a C-terminal LAXT sequence with the Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 1 , respectively, and a sortase substrate comprising a GGG sequence under conditions suitable for sortase-mediated transpeptidation, wherein X represents any amino acid.

11. A method for modifying a protein comprising a sortase recognition motif in a cell or tissue, the method comprising contacting the protein with the Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 1 and a sortase substrate comprising a sortase recognition motif under conditions suitable for sortase-mediated transpeptidation, wherein

(a) the protein comprises a N-terminal sortase recognition motif, and the sortase substrate comprises a C-terminal sortase recognition motif; or

(b) the protein comprises a C-terminal sortase recognition motif, and the sortase substrate comprises a N-terminal sortase recognition motif,

wherein the N-terminal sortase recognition motif comprises the sequence GGG, and the C-terminal sortase recognition motif comprises the sequence LAXT, wherein X represents any amino acid.

12. The Staphylococcus aureus ( S. aureus ) sortase A variant of claim 1 , wherein the amino acid sequence of the Sortase A variant includes two mutations selected from the group consisting of K84R, R99H, R99K, S102C, A104H, E105D, K138I, K138V, K138P, K145E, K152I, D160K, K162R, K162H, T164N, V168I, K177G, K177R, I182F, and K196S.

13. The Staphylococcus aureus ( S. aureus ) sortase A variant of claim 1 , wherein the amino acid sequence of the Sortase A variant includes three mutations selected from the group consisting of K84R, R99H, R99K, S102C, A104H, E105D, K138I, K138V, K138P, K145E, K152I, D160K, K162R, K162H, T164N, V168I, K177G, K177R, I182F, and K196S.

14. The Staphylococcus aureus ( S. aureus ) sortase A variant of claim 1 , wherein the amino acid sequence of the Sortase A variant includes four mutations selected from the group consisting of K84R, R99H, R99K, S102C, A104H, E105D, K138I, K138V, K138P, K145E, K152I, D160K, K162R, K162H, T164N, V168I, K177G, K177R, I182F, and K196S.

15. The Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 1 , wherein the S. aureus Sortase A variant comprises an amino acid sequence that is at least 98% identical to the amino acid sequence provided in SEQ ID NO: 1.

16. The Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 1 , wherein the S. aureus Sortase A variant exhibits a ratio of k cat /K M for a substrate comprising the amino acid sequence LAETG (SEQ ID NO: 5) that is least 60-fold greater than the K cat /K M ratio the sortase exhibits for a substrate comprising the amino acid sequence LPETG (SEQ ID NO: 4).

17. The Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 1 , wherein the S. aureus Sortase A variant exhibits a ratio of k cat /K M for a substrate comprising the amino acid sequence LAETG (SEQ ID NO: 5) that is least 100-fold greater than the K cat /K M ratio the sortase exhibits for a substrate comprising the amino acid sequence LPETG (SEQ ID NO: 4).

18. The Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 1 , wherein the S. aureus Sortase A variant exhibits a ratio of k cat /K M for a substrate comprising the amino acid sequence LAETG (SEQ ID NO: 5) that is least 140-fold greater than the K cat /K M ratio the sortase exhibits for a substrate comprising the amino acid sequence LPETG (SEQ ID NO: 4).

19. The Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 1 , wherein the S. aureus Sortase A variant exhibits a K M for a substrate comprising the amino acid sequence LAETG (SEQ ID NO: 5) that is at least 15-fold less than the K M for substrates comprising the amino acid sequence LPETG (SEQ ID NO: 4).

20. The Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 1 , wherein the S. aureus Sortase A variant exhibits a K M for a substrate comprising the amino acid sequence LAETG (SEQ ID NO: 5) that is at least 20-fold less than the K M for substrates comprising the amino acid sequence LPETG (SEQ ID NO: 4).

21. The Staphylococcus aureus ( S. aureus ) sortase A variant of claim 6 , wherein the amino acid sequence of the Sortase A variant includes two mutations selected from the group consisting of N98D, S102C, A104V, A118S, A118T, F122A, K134G, K134P, E189V, E189F, and E189P.

22. The Staphylococcus aureus ( S. aureus ) sortase A variant of claim 6 , wherein the amino acid sequence of the Sortase A variant includes three mutations selected from the group consisting of N98D, S102C, A104V, A118S, A118T, F122A, K134G, K134P, E189V, E189F, and E189P.

23. The Staphylococcus aureus ( S. aureus ) sortase A variant of claim 6 , wherein the amino acid sequence of the Sortase A variant includes four mutations selected from the group consisting of N98D, S102C, A104V, A118S, A118T, F122A, K134G, K134P, E189V, E189F, and E189P.

24. The Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 6 , wherein the S. aureus Sortase A variant comprises an amino acid sequence that is at least 95% identical to the amino acid sequence provided in SEQ ID NO: 1.

25. The Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 6 , wherein the S. aureus Sortase A variant comprises an amino acid sequence that is at least 98% identical to the amino acid sequence provided in SEQ ID NO: 1.

26. A method for N-terminal protein modification comprising contacting a protein comprising a N-terminal GGG sequence with a the Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 6 , and a sortase substrate comprising a LPXS sequence, respectively, under conditions suitable for sortase-mediated transpeptidation, wherein X represents any amino acid.

27. A method for C-terminal protein modification comprising contacting a protein comprising a C-terminal LPXS sequence with a the Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 6 , respectively, and a sortase substrate comprising a GGG sequence under conditions suitable for sortase-mediated transpeptidation, wherein X represents any amino acid.

28. A method for modifying a protein comprising a sortase recognition motif in a cell or tissue, the method comprising contacting the protein with the Staphylococcus aureus ( S. aureus ) Sortase A variant of claim 6 and a sortase substrate comprising a sortase recognition motif under conditions suitable for sortase-mediated transpeptidation, wherein

(a) the protein comprises a N-terminal sortase recognition motif, and the sortase substrate comprises a C-terminal sortase recognition motif; or

(b) the protein comprises a C-terminal sortase recognition motif, and the sortase substrate comprises a N-terminal sortase recognition motif,

wherein the N-terminal sortase recognition motif comprises the sequence GGG, and the C-terminal sortase recognition motif comprises the sequence LPXS, wherein X represents any amino acid.

Assignments (4)
CONFIRMATORY LICENSE Recorded Jun 23, 2016
From: HARVARD UNIVERSITY
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039131/0242 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2016
From: LIU, DAVID R.
To: HOWARD HUGHES MEDICAL INSTITUTE
Reel/Frame 038281/0209 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 14, 2016
From: LIU, DAVID R.
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 038281/0285 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 12, 2016
From: DORR, BRENT
To: PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Reel/Frame 038257/0034 →
Continuity (3)
Provisional Application 61880515 · Sep 20, 2013
Provisional Application 62043714 · Aug 29, 2014
Related Publication 20160208233A1 · Jul 21, 2016
Cited By (17)
US 12,281,303 US 12,281,338 US 12,351,837 US 12,359,218 US 12,390,514 US 12,406,749 US 12,435,330 US 12,435,331 US 12,473,543 US 12,473,573 US 12,509,680 US 12,516,308 US 12,522,807 US 12,570,972 US 12,624,353 US 12,624,354 US 12,668,815